Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy
| Status: | Completed |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/6/2017 |
| Start Date: | February 2014 |
| End Date: | August 2015 |
This is an observational study. The purpose is to determine the feasibility of using a novel
nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of
brachytherapy treatment. Women with gynecologic cancers treated with brachytherapy as part
of their standard therapeutic regimen will represent the study population.
nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of
brachytherapy treatment. Women with gynecologic cancers treated with brachytherapy as part
of their standard therapeutic regimen will represent the study population.
Brachytherapy is a curative treatment for many malignancies, brachytherapy delivers a high
radiation dose to a very small and well-specified target within a patient with cancer. Yet
there is no current convenient, inexpensive, real time method of confirming the radiation
dose delivered. There is no current monitoring or fail-safe device for radiation oncologists
and their patients if the radiation dose becomes too high, especially to radiation sensitive
organs, or conversely if the target receives too little dose.High dose-rate(HDR)
brachytherapy is a highly advanced radiation-based cancer treatment, where a very small
radioactive source, Iridium-192, is placed in or near the tumor through a catheter or
channel. This provides a high radiation dose to the tumor in 5-15 minutes with a precise
location, while minimizing radiation exposure to surrounding tissue and organs. This
protocol will determine the feasibility of using a novel nano-material based fiber-optic
dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time,
pin-point, in-vivo radiation dose given during radiation therapy treatments. The size of the
device allows placement through a catheter or channel near areas of interest, or within
already placed brachytherapy delivery catheters.
radiation dose to a very small and well-specified target within a patient with cancer. Yet
there is no current convenient, inexpensive, real time method of confirming the radiation
dose delivered. There is no current monitoring or fail-safe device for radiation oncologists
and their patients if the radiation dose becomes too high, especially to radiation sensitive
organs, or conversely if the target receives too little dose.High dose-rate(HDR)
brachytherapy is a highly advanced radiation-based cancer treatment, where a very small
radioactive source, Iridium-192, is placed in or near the tumor through a catheter or
channel. This provides a high radiation dose to the tumor in 5-15 minutes with a precise
location, while minimizing radiation exposure to surrounding tissue and organs. This
protocol will determine the feasibility of using a novel nano-material based fiber-optic
dosimeter (nanoFOD) device, with dimensions less than 1 mm wide, to measure real-time,
pin-point, in-vivo radiation dose given during radiation therapy treatments. The size of the
device allows placement through a catheter or channel near areas of interest, or within
already placed brachytherapy delivery catheters.
Inclusion Criteria:
- Histologically documented neoplasm of the female genital tract.
- Planned brachytherapy as part of standard of care treatment.
- Age > 18 years
- Able to provide and execute informed consent
Exclusion Criteria:
- Any clinical scenario in which the nanoFOD placement or reading would compromise the
treatment efficacy, or endanger the patient in any way.
We found this trial at
1
site
Click here to add this to my saved trials
